Cord blood as third party cells for prophylaxis of graft versus host disease in allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.issn.0254-1785.2012.02.005
- VernacularTitle:第三方脐血预防异基因造血干细胞移植后移植物抗宿主病
- Author:
Xinchuan CHEN
;
Ting LIU
;
Jianjun LI
;
Zhigang LIU
;
Yang DAI
;
Yun TANG
;
Jing CAI
;
Yongqian JIA
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Cord blood;
Graft vs host disease
- From:
Chinese Journal of Organ Transplantation
2012;33(2):86-89
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the efficacy of co-infusing cord blood (CB) as the third party cells on graft versus host disease (allo-GVHD) prophylaxis after unrelated or haploidentical donor allogeneic hematopoietic stem cell transplantation (allo-HSCT).MethodsFrom 2007 to 2011,41 patients receiving unrelated or haploidentical donor allo-HSCT were analyzed retrospectively.Twenty-five patients received one unit of HLA 4/6-6/6 matched CB one day before SCT as CB group,and median MNC dose was (1.64 ± 0.49) × 107/kg.Sixteen cases not receiving CB served as control group.All patients received antithymocyte globulin,cyclosporine,methotrexate,and mycophenolate mofetil as GVHD prophylaxis.The incidence and severity of aGVHD,and treatment-related mortality were compared between two groups.ResultsThe main clinical characteristics in both groups were comparable.The cumulative incidence of aGVHD in CB group and control group was 44.0％ versus 68.8％ respectively (x2 =2.403,P＞0.05).The cumulative incidence of grades Ⅲ to ⅣV aGVHD in CB group and control group was 16.0％ and 37.5％ respectively (x2 =2.445,P＞0.05).The 100-day treatment-related mortality in CB group and control group was 12.0％ and 12.5％ respectively (x2 =0.002,P＞0.05).ConclusionCord blood as the third party cells might reduce the incidence and severity of aGVHD in unrelated or haploidentical donor HSCT.The efficacy and the mechanism of this strategy need to be further explored by prospective randomized controlled trials.
